Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CAL 02

Next Previous
Drug Profile

CAL 02

Alternative Names: CAL-02

Latest Information Update: 25 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Combioxin
  • Developer Eagle Pharmaceuticals; LASCCO
  • Class Antibacterials
  • Mechanism of Action Bacterial toxin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Community-acquired pneumonia

Most Recent Events

  • 05 Jun 2025 Eagle Pharmaceutical suspends a phase II trial in Community-acquired pneumonia (Adjunctive treatment) in Argentina, Brazil, Belgium, Canada, Chile, Colombia, Czech Republic, France, Georgia, Greece, Hungary, Latvia, Peru, Romania, Serbia, Slovakia, South Africa, Spain, USA (IV) (NCT05776004)
  • 28 Nov 2024 No recent reports of development identified for phase-I development in Community-acquired-pneumonia(In the elderly, In adults) in Belgium (IV, Infusion)
  • 28 Nov 2024 No recent reports of development identified for phase-I development in Community-acquired-pneumonia(In the elderly, In adults) in France (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top